whilst 29 patients (non-ribavirin group) received best supportive care including corticosteroids. The median forced expiratory volume in 1 s dropped 20% (IQR 15-32) from baseline in the ribavirin group versus 18% (IQR 13-30) in the non-ribavirin group during infection. In 84% of patients treated with ribavirin and 59% of the non-ribavirin group, graft function recovered within 30 days (P=0.02). New onset of BOS developed within 6 months in 5% of the ribavirin group versus 24% of the non-ribavirin group (P=0.02). Conclusions: Treatment of PV after lung/heart-lung transplantation with oral ribavirin seems to be associated with earlier recovery of graft function and to prevent BOS.
Community-acquired respiratory viruses (CARVs), including members of the Paramyxoviridae (PV) family -respiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (hMPV) -are increasingly recognized as pathogenic in lung transplant recipients [1] [2] [3] [4] [5] [6] . PV illness in healthy adults is typically mild and limited to the upper respiratory tract. In immunocompromised patients, lower respiratory tract involvement in viral infections is more common and has increased morbidity and mortality. Higher susceptibility might be explained by continuous graft exposure to the environment, impaired cough reflex and mucociliary clearance, along with interruption of the blood and lymphatic vessels [3] . A cumulative incidence of PV infection between 5 and 13% has been reported in lung transplant populations studied over periods ranging from 5 to 7 years [4] . The acute effects of PV infection in lung transplant recipients include upper and lower respiratory tract symptoms, deteriorating graft function and possible association with acute rejection and bronchiolitis obliterans syndrome (BOS) [5] [6] [7] [8] . Data from previously published reports have suggested a BOS incidence between 6 and 40% in lung/heart-lung recipients in the first year following CARV infection [3] [4] [5] [7] [8] [9] [10] .
Ribavirin, a purine nucleoside analogue with efficacy against many RNA viruses, including RSV, hMPV and PIV, represents a viable treatment option for PV infection. Data on ribavirin-treatment in lung/heart-lung recipients are limited [11] [12] [13] [14] [15] , and the clinical efficacy of ribavirin for therapy of PV infections is uncertain in immunocompromised patients. Several retrospective studies have suggested that therapy may facilitate symptomatic improvement in lung/heart-lung patients, but no comparative studies have been performed and the
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Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections Introduction effect on BOS is unknown. The purpose of this study was to define the efficacy of ribavirin therapy in lung/ heart-lung recipients infected with PV.
Methods

Study design
A prospective, observational study was conducted in the lung/heart-lung outpatient clinic of Hannover Medical School from 1 September 2006 until 30 April 2009. During this period, 585 lung/heart-lung transplant patients attended the department as a part of their regular follow-up. Inclusion criteria were patients who had undergone lung transplant >6 months before, including single-lung, double-lung or multiorgan recipients, who had been diagnosed with PV infection, including RSV, hMPV and PIV. Six patients with concomitant coinfection (bacterial, viral or fungal) or airway complications at presentation were excluded due to their potential confounding risk factor for BOS. No patients with recurrent PV infections were included more than once.
Monitoring and sampling for illness
All transplant recipients receive individually tailored, frequent, centre-based follow-up on a lifelong basis. At each consultation, spirometry, home spirometry data analysis, chest X-ray and routine blood testing were performed. Spirometry was performed according to American Thoracic Society/European Respitory Society guidelines [16] . Standard maintenance immunosuppression consisted of a triple-drug regimen including a calcineurin inhibitor, prednisolone, and a cell-cycle inhibitor or a mammalian target of rapamycin inhibitor. Induction therapy was not used during the surveillance period. All lung/heart-lung recipients in our programme were instructed to perform daily self-monitoring via home spirometry. With the onset of new respiratory symptoms, fever or declining home spirometry, patients were instructed to contact the transplant centre to arrange urgent reassessment.
Home spirometry is routinely processed by an electronic spirometry system (VIASYS Healthcare, Hoechberg, Germany) to collect and store relevant expiratory flow-volume parameters including the forced expiratory volume in 1 s (FEV1). The FEV1 is presented on the spirometer's digital display for self-monitoring purposes. In addition, this value is compared with individually-defined predicted FEV1 (baseline FEV1) values and informs the patient of their current lung function trend compared with this baseline value.
Patients with features suggestive of a lower respiratory tract infection (defined as a FEV1 decline >10% from previous value, new pulmonary infiltrates on chest X-ray or new onset of cough, sputum, shortness of breath, wheezing or hypoxia) underwent bronchoscopy with bronchoalveolar lavage (BAL). Nasopharyngeal swabs were performed if bronchoscopy was not feasible or if only symptoms of upper respiratory tract infection were present.
Management of paramyxovirus infections
All patients with proven PV were planned to receive oral ribavirin for 14 days in a dosage of 15-20 mg/kg/day in two divided doses. Patients with contraindications for ribavirin therapy were followed-up as the non-ribavirin group. Contraindications to ribavirin included renal failure (creatinine clearance <30 ml/min), anaemia (haemoglobin <9 g/dl) or leucopaenia (<3×10 9 /l) or known intolerance to ribavirin. The same criteria were applied when deciding to prematurely stop ribavirin treatment. Other antiviral drugs (acyclovir, valganciclovir) were suspended during ribavirin treatment.
Patients with PV infection and contraindications for ribavirin received supportive treatment consisting of temporarily increasing the maintenance dose of oral prednisolone in (symptomatic) patients. The usual dose was 0.5 mg/kg prednisolone, to a maximum dose of 60 mg/day for 7 days, with subsequent weaning by 5 mg every second day to the previous maintenance level.
Outcome
Patients were evaluated during a follow-up period of 6 months after infection or until 30 October 2009 for recovery of graft function, time to recovery, acute rejection, BOS, change in BOS stage (stage 0-3, irrespective of stage 0p), 6-month survival or graft loss (death or re-transplantation).
All patients without lung function recovery underwent follow-up re-sampling to confirm the negative virus status during routine follow-up or 7 days after commencing treatment. Re-attendance at our outpatient clinic was arranged for 2 weeks after PV infection. Prior to enrolment, the project had been approved by the Institutional Review Board. All patients gave informed consent and signed consent forms approved by the Hannover Medical School Institutional Review Board. There was no financial support from the pharmaceutical industry.
Viral detection
Nasal and oropharyngeal swabs were used only if BAL was not feasible or isolated symptoms of upper respiratory tract infection were present. In swabs, PCR was used as the method for virus detection; in BAL, antigen testing was performed first. BAL fluids were submitted for direct immunofluorescence antigen testing with monoclonal antibodies specific for RSV, PIV I-III and hMPV (all from Virion, Ochsenhausen, Germany).
Reverse transcriptase real-time PCR was performed using a commercially available kit according to the manufacturer's instructions (Real accurate respiratory reverse transcriptase PCR Kit; Pathofinder, Maastricht, the Netherlands) to allow the detection of 12 different CARVs: influenza virus types A and B, respiratory syncytial virus types A and B, PIV types 1-4, coronavirus types OC43 and 229E, rhinovirus, and hMPV. PCR testing was performed if antigen testing proved negative despite a clinical history suggestive of CARV infection. Virus infection was defined as any virus detection (by antigen testing and/or PCR) [8] .
Definitions PV infection was defined as any detection of RSV, PIV or hMPV regardless of clinical symptomatology. Home spirometry recovery was specified as 50%, 75% and 90% recovery of the ∆ drop in home spirometry (∆ = baseline FEV1 before infection -FEV1 infection).
Symptoms of upper respiratory tract infection were defined as new-onset sore throat, sneezing, nasal congestion or hoarseness. Symptoms of lower respiratory tract infection were defined as new onset of cough, sputum, shortness of breath, wheezing or hypoxia. Constitutional symptoms were rated positive if fever, arthralgia, myalgia or malaise were present.
Histopathology of allograft rejection and clinical staging of BOS were performed according to the current criteria established by the International Society of Heart and Lung Transplantation [17, 18] . Acute rejection was defined as histological classification equal to or greater than A1 in any biopsy or a reversible deterioration in graft function responding to steroid pulse therapy in the proven absence of coexisting infection.
BOS progression was defined as progression to a higher BOS stage during follow-up or FEV1 decline >20% from the previous value. Graft function recovery was defined by a recovery in office spirometry to a FEV1 >90% of the baseline before PV infection.
Data analysis
The clinical endpoint of the study was new BOS onset within 6 months after PV infection. Further objectives were the time to FEV1 recovery, acute rejection, BOS progression, survival or graft loss after 6 months. Data are reported as medians with minimum-maximum or IQR. All reported P-values are two-sided, unless otherwise indicated. For all analyses, P<0.05 was considered statistically significant. Categorical variables were analysed by chi-squared test or Fisher´s exact test. Medians were compared with the MannWhitney test and the non-parametric Kruskal-Wallis H-test. Cox stepwise forward regression analysis was performed for BOS-free survival. All variables with P<0.10 were included, and variables with P>0.10 were excluded in a multivariate analysis. For KaplanMeier and Cox regression analysis, BOS-free survival 6 months after infection and time to recovery of home spirometry were calculated. Table 1 .
Results
Patients
Most cases occurred during October-March. A total of 38 patients received ribavirin + steroids for RSV (n=24), hMPV (n=4), and PIV (n=10) for 14 days. In 10 individuals therapy was stopped prematurely (median 8 days, IQR 6-10 days) due to haemolysis (n=5), renal failure (n=4) and nausea (n=1). A total of 29 patients (RSV n=19, hMPV n=1, and PIV n=9) were treated with supportive care due to contraindications for ribavirin (renal failure n=21, 72%; anaemia/haemolysis n=6, 21%; and leucopaenia n=2, 7%).
Nasopharyngeal and oropharyngeal swabs were performed in 22 patients and proved positive for PV in 12 (55%) cases (PIV III n=4, PIV II n=2, RSV n=5, and hMPV n=1). BAL was performed in 59 (88%) patients and detected PV in 55 (88%) cases (PIV III n=10, PIV II n=1, PIV I n=2, RSV n=38, hMPV n=4).
Outcomes
Most attendances at the outpatient clinic were emergency visits (n=56, 83.5%). Reasons for attendance included deteriorating home spirometry (83.3%), constitutional symptoms (22.4%), upper respiratory tract infection (70.1%), lower respiratory tract infection (52.1%) or fever (>38.5°C, 12.4%). There were no patients without respiratory symptoms and/or deterioration in lung function within our cohort. Deterioration in FEV1 >10% of baseline was observed in 51/67 (76%) individuals. The mean FEV1 decline in PV-positive patients was 20% (IQR 12-26) from their previous value. New hypoxia occurred in 5 (8%) patients, new infiltrates on chest X-rays accounted for 7 (10%) patients.
A total of 10 patients (15%) were hospitalized due to PV infection. Of these, 4 patients developed acute rejection (A≥1), defined by continued decline in lung function despite 1 week of therapy. Five patients were concomitantly treated with antimicrobials during antiviral therapy due to bacterial coinfection in the clinical course. New BOS developed in 9 patients following PV infection (RSV n=6, PIV n=3), five of whom required initial hospital treatment. A patient treated with ribavirin subsequently required intubation following hMPV diagnosis and died 3 weeks later.
Association of ribavirin and outcomes
No significant differences between ribavirin/no ribavirin treatment for gender, underlying disease, postoperative years, type of transplant or immunosuppressive regimen were identified ( Table 2) . Recovery of graft function (FEV1, home spirometry), time to recovery of home spirometry (50%, 75%, and 90%) and time to onset of BOS differed significantly between the ribavirin and non-ribavirin treatment groups (Figures 1 and  2 Figure 1A and 1B). A total of 32 patients (84%) treated with ribavirin had full restoration of graft function compared with only 17 patients (59%) without ribavirin after 30 days. A total of 17 patients required repeat assessment after 7 days due to a lack of any evident recovery in lung function. Of these patients, 12 exhibited continuing symptoms -10 patients were still virus positive after 7 days. Treatment (ribavirin or supportive care) was continued in all of these patients. Ribavirin treatment was extended in 3 patients for a further 7 days due to positive virus detection after 14 days of therapy. After this, patients were re-sampled and turned virus-negative. Two patients remained virus-positive when discontinuing ribavirin treatment early, but turned virus-negative when re-sampling the patients 7 days later.
Out of 51 BOS-naive patients, 9 patients (n=2 ribavirin group and n=7 non-ribavirin) developed newly diagnosed BOS during follow-up after a median of 42 days (IQR 22-58 days) from presentation. In eight of these patients the initial decline in FEV-1 persisted, consistent with a diagnosis of BOS. A patient not treated with ribavirin initially recovered, but subsequently developed BOS 55 days later. In all patients, the diagnosis of BOS was made during the subsequent 3-month surveillance period after presentation (Figure 2) . Overall BOS incidence after 1 year in CARV-negative patients during the study period was 9% in our centre (n=578). A total of 16 patients (24%) were previously diagnosed with BOS. Change in BOS status was seen in one patient from each group. Time after transplant, ribavirin treatment and recovery in lung function proved significant covariates in the Cox regression for onset BOS (details in Table 3) , with all other variables eliminated as nonsignificant (including virus type).
Discussion
This is the first study to assess the effects of oral ribavirin treatment in lung/heart-lung recipients with PV disease. Although the study was non-randomized, our data suggest that ribavirin treatment in PV infection reduces the time to recovery in lung function and prevents new BOS in the ensuing 6 months.
The incidence of surveillance detecting CARVs in lung/ heart-lung transplant outpatients was about 8% in a single-season surveillance study from our centre. In this study, CARV infection led to mean declines in the FEV1 of 11% from baseline, as well as causing hypoxia in about 10% of affected patients [5] . Abnormal chest X-ray was described in up to 20% of CARV-infected lung/heartlung patients [6, 8] . In the current study, the overall incidence of PV infection in lung transplant outpatients was 5 per 100 patients. The rates of hospitalization (15%) hypoxaemia (7%) and chest X-ray abnormalities of our patients (10%) were comparable with other studies.
The main effect of CARV infections is increased risk for new-onset BOS. The risk to develop BOS during the following year after CARV infection has been assessed as about 12-25% (hazard ratio 2.05-4.05) in previous studies [5, 8] , with PV being identified as a particular BOS-inducing risk [8] . A recent single-centre study has shown that hMPV is a leading cause of acute respiratory tract illness in lung transplant recipients. The incidence and clinical spectrum at presentation are similar to RSV, although the latter seems to be associated with a higher risk of chronic rejection [6] . Accurate risk stratification for various viruses in terms of BOS, however, cannot be made from current data, including our study. CARV infection did not trigger progression of the disease in patients with a previous diagnosis of BOS in one study [8] . Until now, there has been no satisfactory explanation for this observation, and the small cohort with established BOS and PV infection (n=16) in this study is too small to draw any conclusions from our data.
CARV infection has also been associated with acute allograft rejection in a small series of lung/heart-lung recipients [2] . No association with acute rejection episodes were identified in the present study. CARV infections are difficult to discriminate from acute rejection. Perivascular infiltrates, the hallmark of acute rejection, were observed in lung/heart-lung recipients with viral and other infections and may impair interpretation of biopsy results [19] .
Except for the availability of specific anti-influenza antivirals, treatment options for viral respiratory infections are mainly supportive. Reports of the use of oral ribavirin therapy for PV infections are limited to case series and reports, primarily in patients after haematopoietic stem-cell transplantation. Its use for treating PV infection is off-label in most countries. Ribavirin has been shown to have in vitro activity against RSV and the aerosolized form has been approved for the treatment of lower respiratory tract disease due to RSV in certain at-risk populations [20, 21] . Data for intravenous ribavirin therapy also remain limited [1, 22] . Drawbacks with inhaled ribavirin include difficulties in administration, requiring continuous inhalation, along with associated risks of bronchoconstriction and respiratory distress, which may necessitate discontinuation. In addition, aerosol ribavirin is considered to be potentially hazardous and teratogenic to healthcare workers as well as being excessively expensive in comparison with oral ribavirin (€3,000 versus €30 per day) without evidence of improved clinical efficacy [23] . Considering these limitations, widespread acceptance of the nebulized administration is missing.
This study brings no definite proof of the antiviral effect of ribavirin, but may suggest a significant clinical benefit. Our results do not allow an assessment of the potential mechanisms (for example, antiviral effects and immunomodulation) of ribavirin's apparent beneficial effect. The mode of action of systemically delivered ribavirin in RSV infection is unclear and the penetration to the respiratory epithelium after systemic application is questionable. Data from in vitro studies of hepatitis C infection suggest immunomodulatory effects of the drug [24, 25] .
The optimal duration of ribavirin therapy is unknown, although treatment for 14 days led to successful virus elimination in 25 out of 28 (89%) of our patients. Of particular note, ribavirin was contraindicated in 42% of PV-infected recipients in our study and was terminated early in another quarter of cases due to adverse effects. Twice-weekly monitoring of blood cell counts and renal function is mandatory whilst under therapy. Compared with bone marrow transplant recipients treated with inhaled or intravenous ribavirin, more frequent discontinuation due to toxicity was necessary in our patient population [21, 22] . The most likely explanation for this remains combined toxicity of ribavirin and that inherent to the maintenance medication required after lung transplantation.
Published data on the treatment of RSV disease in other solid organ transplant recipients is also extremely limited. Experience in stem cell transplant populations suggests that the use of aerosolized ribavirin may reduce mortality associated with severe RSV infections, particularly in infections involving the lower airways.
In stem cell recipients with non-RSV paramyxovirus infections, combined use of intravenous immunoglobulin and ribavirin is controversial. Some authors also support the use of intravenous immunoglobulin in lung transplant recipients [12] or in combination with ribavirin [26] . Case reports and animal data suggest that ribavirin and intravenous immunoglobulin can be considered for the management of severe cases of hMPV, but supportive care remains the mainstay of treatment [8, 27] . To our knowledge, RSV-specific intravenous immunoglobulin is not used in most experienced lung/ heart-lung transplant centres.
It is important to note that this study merely illustrates a single-centre experience and contains some clear design limitations. Patients were not randomized to a control or treatment group, with patient selection for treatment with oral ribavirin being limited to the absence of contraindications. To our knowledge none of the contraindications for ribavirin (for example, renal failure, leucopaenia and so forth) are established risk factors for BOS. All patients had symptoms of either upper or lower respiratory tract infection or deteriorating graft function. There might be other reasons despite CARV infection for their clinical course. Technical limitations of direct immunofluorescence, antigen testing and PCR making the technique prone to produce false positive/negative results have to be considered.
In conclusion, we have shown that oral ribavirin was variably well tolerated, but seemed to be associated with better outcome after PV infection in lung/ heart-lung recipients. Ease of delivery and enhanced safety of oral therapy to both staff and patients represents a major advance over standard nebulized ribavirin. Development of novel, less toxic chemotherapeutic agents to treat this infection, however, would be desirable [28, 29] . Additional goals in PV management are prevention of infection and the future development of effective vaccines [30] . Future multicentre randomized controlled trials should study the effect of antiviral drugs in the lung transplant population.
